Regulus Therapeutics Inc.
RGLS
Classificação em ações
#17339
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Preço da ação
$8.16
Última sincronização: 2025-06-26
Valor de mercado
$234.57M
Variação (1 dia)
0.00%
Variação (1 ano)
-88.86%
País
US
Negociar Regulus Therapeutics Inc. (RGLS)
Categoria
Healthcare
Rácio P/S de Regulus Therapeutics Inc. (RGLS)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Regulus Therapeutics Inc., o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Regulus Therapeutics Inc. de 2026 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
